Cesamet

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

Cannabinoids in pharmaceutical development

The development of cannabinoids in the pharmaceutical industry has exploded over the past few year